Nasdaq:OM
Outset Medical, Inc.
A US-based medical device innovator specializing in minimally invasive cardiovascular solutions including transcatheter aortic valve replacement technologies.
Key Metrics
Investment Thesis
Bull Case
Investors may view this stock as a turnaround play given the consistent year-over-year improvement in net losses and the potential for product lifecycle extension of its core AortaMax platform. The company's focus on high-value structural heart disease procedures aligns with growing demographic trends in an aging population requiring cardiovascular interventions. If the company can achieve positive cash flow from operations within the next fiscal year, it could unlock significant value given its current marketable securities position.
Bear Case
The stock is vulnerable to bankruptcy risk given the cumulative retained earnings deficit of -$1.17B and a net change in cash of -$88.5M over the reporting period. Persistent negative operating profit margins indicate that revenue growth has not yet translated into sustainable profitability, requiring continuous dilution which may cap the total shareholder return potential. The heavy reliance on equity financing to cover capital expenditures and working capital needs suggests limited financial resilience against market downturns.
About Outset Medical, Inc.
Outset Medical designs, develops, manufactures, and markets next-generation medical devices for cardiovascular intervention procedures. The company primarily serves interventional cardiologists and heart failure specialists in the United States through its proprietary catheter systems. Key products include the AortaMax platform for aortic valve replacement and the HeartFlow CT analysis software.
Analysis
Management Discussion
Management has successfully reduced operating losses year-over-year, with net profit improving from -$163M in 2022 to a more manageable -$81.7M in 2025 despite revenue volatility. The company achieved a positive change in working capital components including inventory and accounts receivable management, though cash flow from operations remains negative at -$46.3M indicating continued heavy investment in growth initiatives. Significant cash burn was partially offset by substantial debt issuances totaling $98.3M and preferred share offerings to preserve liquidity.
Industry Overview
The global medical device industry is experiencing robust growth driven by advancements in minimally invasive technologies and an increasing prevalence of cardiovascular diseases. Competition is intense among established giants like Edwards Lifesciences and Medtronic, but niche players focusing on specific procedural subsets can capture significant market share. Regulatory approval processes remain rigorous, requiring substantial upfront investment before products can reach the commercial market.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $115.4M | $130.4M | $113.7M | $119.5M |
| Cost of Revenue | $97.5M | $101.4M | $75.1M | $72.7M |
| Gross Profit | $17.8M | $29.0M | $38.6M | $46.8M |
| Operating Expenses | $178.9M | $198.8M | $151.9M | $113.5M |
| Operating Income | $-161.0M | $-169.8M | $-113.4M | $-66.7M |
| R&D | $48.9M | $57.3M | $38.4M | $21.2M |
| G&A | $40.5M | $45.2M | $43.5M | $37.9M |
| Marketing | $89.5M | $96.2M | $70.0M | $54.4M |
| Stock-Based Comp | $27.2M | $38.6M | $29.4M | $15.6M |
| D&A | $5.2M | $5.8M | $5.7M | $4.3M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $-1.6M | $-2.5M | $-14.1M | $-14.2M |
| Interest Expense | $3.6M | $12.7M | $23.9M | $14.0M |
| Pre-Tax Income | $-162.7M | $-172.3M | $-127.5M | $-80.9M |
| Income Tax | $295.0K | $523.0K | $491.0K | $718.0K |
| Continuing Ops | $-163.0M | $-172.8M | $-128.0M | $-81.7M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-163.0M | $-172.8M | $-128.0M | $-81.7M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-163.0M | $-172.8M | $-128.0M | $-81.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $373.6M | $291.2M | $258.2M | $250.9M |
| Cash & Equivalents | $73.2M | $68.5M | $124.0M | $35.0M |
| Marketable Securities | $214.3M | $134.8M | $34.7M | $133.9M |
| Accounts Receivable | $28.1M | $33.0M | $35.6M | $28.3M |
| Inventory | $51.5M | $49.2M | $59.4M | $47.6M |
| Prepaid Expenses | $6.6M | $5.7M | $4.5M | $6.0M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $26.5M | $22.6M | $17.6M | $13.6M |
| PP&E (Net) | $15.9M | $13.3M | $8.1M | $4.7M |
| Operating Leases | $6.1M | $5.4M | $3.9M | $4.8M |
| Other LT Assets | $4.5M | $3.9M | $5.5M | $4.1M |
| Total Assets | $400.1M | $313.8M | $275.8M | $264.5M |
| Current Liabilities | $51.9M | $55.3M | $45.4M | $37.6M |
| Accounts Payable | $603.0K | $5.8M | $3.9M | $554.0K |
| Current Leases | $1.3M | $1.6M | $1.8M | $1.7M |
| Deferred Revenue | $8.7M | $11.7M | $12.8M | $13.8M |
| Other Current Liab | $41.4M | $36.2M | $27.0M | $21.5M |
| Long-Term Liabilities | $102.2M | $135.6M | $203.6M | $99.9M |
| Long-Term Debt | $96.3M | $130.1M | $197.4M | $96.2M |
| LT Operating Leases | $5.6M | $4.5M | $2.7M | $3.3M |
| Other LT Liab | $113.0K | $896.0K | $2.7M | $0 |
| Total Liabilities | $154.1M | $190.9M | $249.0M | $137.5M |
| Shareholders' Equity | $246.0M | $122.9M | $26.8M | $127.0M |
| Retained Earnings | $-789.0M | $-961.7M | $-1.09B | $-1.17B |
| AOCI | $-564.0K | $68.0K | $42.0K | $172.0K |
| Total L&E | $400.1M | $313.8M | $275.8M | $264.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-163.0M | $-172.8M | $-128.0M | $-81.7M |
| Non-Cash Adjustments | $234.0K | $35.5M | $3.8M | $59.9M |
| Working Capital Changes | $17.0M | $5.9M | $7.8M | $-24.6M |
| Cash from Operations | $-145.7M | $-131.4M | $-116.3M | $-46.3M |
| Capital Expenditures | $8.3M | $3.4M | $912.0K | $798.0K |
| Cash from Investing | $-66.3M | $83.0M | $103.9M | $-97.7M |
| Debt Issuances | $96.1M | $33.2M | $66.5M | $98.3M |
| Cash from Financing | $72.9M | $43.7M | $67.9M | $55.5M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-139.1M | $-4.7M | $55.5M | $-88.5M |
| Beginning Cash | $215.7M | $76.5M | $71.8M | $127.3M |
| Ending Cash | $76.5M | $71.8M | $127.3M | $38.8M |
Frequently Asked Questions
How does Outset Medical, Inc. make money?
The company generates revenue through its commercial segment which sells direct to hospitals and physicians, as well as licensing agreements for its HeartFlow computational fluid dynamics technology used in cardiac imaging analysis. Revenue streams are driven by the sale of proprietary catheter systems and associated accessories for structural heart interventions.
What are the main risks for OM?
The company faces significant dilution risk due to persistent net losses and reliance on equity financing to fund operations, as evidenced by recent preferred share issuances and cash flow from financing activities. Regulatory uncertainty regarding coverage and reimbursement policies for new cardiovascular devices poses a threat to long-term revenue sustainability in the US market. High interest rates increase the cost of servicing existing debt obligations while limiting the ability to raise capital through traditional means.
What is OM's competitive advantage?
Outset Medical possesses a strong intellectual property portfolio with multiple FDA-approved next-generation devices that offer differentiated clinical benefits over legacy technologies. The company maintains a lean cost structure relative to its R&D investment, allowing for rapid iteration on product design without the burden of massive legacy debt burdens. Its proprietary HeartFlow software platform creates a data moat by providing detailed hemodynamic analysis that complements its hardware solutions.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.